Natco Pharma Q4 Results
- BSE: 524816
- NSE: NATCOPHARM
- ISIN: INE987B01026
- Sector: Biotechnology & Drugs
BSE
902.40
-49.85 (-5.23%)
-49.85 (-5.23%)Volume1.75 L
Updated: Fri 14 Aug, 2026 | 15:52:00
NSE
907-44.70 (-4.70%)
-44.70 (-4.70%)Volume2.49 M
Updated: Fri 14 Aug, 2026 | 15:29:59
Technical Trends
Long TermConsiders price movement over the last 6 months
Not Available
Short TermConsiders price movement over the last 1-2 weeks
Not Available
- Bearish
- Moderately Bearish
- Neutral
- Moderately Bullish
- Bullish
Insight: Trends unavailable at the moment.
Q4 Results Highlights
- Total Income₹739.10 Cr.(-39.47%)
- Operating Profit₹77.20 Cr.(-82.84%)
- Profit After Tax₹267.90 Cr.(-34.11%)
- Operating Margin10.45%(-71.65%)
Note: Comparison is on YoY basis
Quarterly - Natco Pharma Q4 Results
*All figures in crores except per share values
| Fiscal Period | Mar 26 | Dec 25 | QoQ Comp | Mar 24 | YoY Comp |
|---|---|---|---|---|---|
| Total Operating Expense | 661.90 | 534.80 | 23.77% | 626.50 | -14.17% |
| Depreciation/ Amortization | 50.40 | 46.20 | 9.09% | 55.50 | -48.73% |
| Operating Income | 77.20 | 112.50 | -31.38% | 441.80 | -82.84% |
| Net Income | 267.90 | 151.50 | 76.83% | 386.30 | -34.11% |
| Other Operating Expenses Total | 298.30 | 196.10 | 52.12% | 285.90 | 12.86% |
| Net Income Before Taxes | 144.10 | 161.10 | -10.55% | 477.60 | -71.52% |
| Total Revenue | 739.10 | 647.30 | 14.18% | 1,068.30 | -39.47% |
| Selling/ General/ Admin Expenses Total | 158.50 | 159.40 | -0.56% | 142.50 | -0.56% |
| Diluted Normalized EPS | 14.96 | 8.46 | 76.83% | 21.57 | -34.11% |
EQUITY QUICK LINKS
FROM MARKETS
Trending Stocks
✕
Wait for it…
Oops! Looks like you have exceeded the limit to bookmark the image. Remove some to bookmark this image.